MoONPs/ZIF-8 composite material prepared via RCVD for photodegradation of dyes.

Toxic wastewaters from the textile industry have made its way into rivers and other waterways, posing a serious health treat on both human and wildlife. Herein, this data set presents the potential use of MoO nanoparticles supported on ZIF-8 in the photodegradation of a cationic dye molecule. The data presented in this article report a concise description of experimental conditions for the spray-dried ZIF-8 synthesis and subsequent deposition of MoO nanoparticles via rotary chemical vapor deposition (RCVD).

Genetic diversity and biogeography of T. officinale inferred from multi locus sequence typing approach.

Taraxacum officinale (Asteraceae) is widely distributed weedy plant used as a traditional medicinal herb. The population genetics and historical biogeography of this plant have remained relatively unexplored. This study explores phylogeny, population genetics and ancestral reconstructions adopting multi locus sequence typing (MLST) approach.

Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.

Objectives: To assess risk factors for a first thrombotic event in confirmed antiphospholipid (aPL) antibody carriers and to evaluate the efficacy of prophylactic treatments.

Methods: Inclusion criteria were age 18-65 years, no history of thrombosis and two consecutive positive aPL results. Demographic, laboratory and clinical parameters were collected at enrolment, once a year during the follow-up and at the time of the thrombotic event, whenever that occurred.

Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.

Objectives: To asses risk factors for a first thrombotic event in antiphospholipid antibody (aPL) positive carriers and evaluate the efficacy of prophylactic treatments.

Methods: Recruitment criteria were age 18-65 years, no history of thrombosis, positivity for lupus anticoagulant and/or IgG/IgM anticardiolipin antibody (aCL) on > or =2 occasions at least 6 weeks apart. Demographic, laboratory and clinical parameters were collected at enrolment and at the time of the thrombotic event.